Publication: Optimal use of perampanel in asian patients with epilepsy: Expert opinion
Issued Date
2021-01-01
Resource Type
ISSN
1178203X
11766336
11766336
Other identifier(s)
2-s2.0-85111575860
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Therapeutics and Clinical Risk Management. Vol.17, (2021), 739-746
Suggested Citation
Yotin Chinvarun, Chin Wei Huang, Ye Wu, Hsiu Fen Lee, Surachai Likasitwattanakul, Jing Ding, Takamichi Yamamoto Optimal use of perampanel in asian patients with epilepsy: Expert opinion. Therapeutics and Clinical Risk Management. Vol.17, (2021), 739-746. doi:10.2147/TCRM.S316476 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/76558
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Optimal use of perampanel in asian patients with epilepsy: Expert opinion
Abstract
Perampanel is a once-daily, first-in-class AMPA receptor antagonist approved for the treatment of epilepsy and exhibits broad-spectrum efficacy in a range of seizure types when used as both monotherapy and adjunctive therapy. Clinical studies and real-world evidence have demonstrated the advantages of initiating perampanel at low doses and utilizing a slow titration strategy. Initiating perampanel at an early stage has also been shown to be associated with better patient outcomes. However, the optimal use and place of perampanel in clinical practice has not yet been clearly defined for the Asian patient population. Use of perampanel in clinical practice varies markedly across the Asia region because of variation in knowledge, attitudes, and practice. There is currently no specific guidance on best practices for prescribing perampanel in Asian patients or how to optimize treatment strategies to maximize adherence. A group of epilepsy experts attended a virtual meeting in September 2020 to discuss their experience with using perampanel in the Asian practice setting, including their views regarding appropriate patient populations, optimal starting and maintenance doses, optimal titration regimens, key barriers to adherence, and prevention and management of adverse events. This article summarizes key clinical and real-world evidence for perampanel and consolidates the experts’ opinions on optimization of perampanel prescribing and adherence in real-world practice, providing practical strategies for clinicians to implement to improve outcomes for people with epilepsy in Asia.